Intermittent hormonal therapy in the treatment of metastatic prostate cancer: A randomized trial

BJU International

Volumn 110, Issue 9, 2012, Pages 1262-1269

  Mottet, Nicolas ^a   Van Damme, Jean ^b   Loulidi, Salim ^c   Russel, Christoph ^c   Leitenberger, Armin ^d   Wolff, Johannes M ^e  

^a Clinique Mutualiste de la Loire   (France)

^b CHG de Lons le Saunier   (France)

^c Chirurgie ^*  (Germany)

^d Zentral Krankenhaus St   (Germany)

^e Department of Urology   (Germany)

Author keywords

hormonal therapy; intermittent therapy; metastatic prostate cancer; quality of life

Indexed keywords

FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; ARTICLE; BONE PAIN; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HOT FLUSH; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUPROLIDE; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TABLETS; TREATMENT OUTCOME;

EID: 84867744623     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11120.x     Document Type: Article

References (32)

1. Heidenreich A, Bolla M, Joniau S, et al,. EAU guidelines on prostate cancer. March 2009. Available at: http://www.uroweb.org/nc/professional- resources/guidelines
2. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238-44
3. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D,. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 2275-82
4. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD,. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate specific antigen. Cancer 1993; 71: 2782-90
5. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59
6. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G,. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 233-40
7. Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N,. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol 1999; 3: 287-92
8. Spry NA, Kristjanson L, Hooton B, et al,. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 1083-92
9. Bouchot O, Lenormand L, Karam G, et al,. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 543-9
10. Klotz L, O'Callaghan CJ, Ding K, et al,. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 2011; 29 (Suppl. 15): 2925; abstract 4514
11. Tunn U, Eckhart O, Kienle E, Hillger H,. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy-first results of a randomised prospective phase-III clinical trial (AUO study AP06/95). Eur Urol Suppl 2003; 2: 24
12. de Leval J, Boca P, Yousef E, et al,. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomised multicenter trial. Clin Prostate Cancer 2002; 1: 163-71
13. Lane TM, Ansell W, Farrugia D, et al,. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 117-22
14. Calais da Silva FE, Bono AV, Whelan P, et al,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-77
15. Miller K, Steiner U, Lingnau A, et al,. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105]. Presented at American Society of Clinical Oncology; June 1-5, 2007; Chicago, IL, USA
16. Lukacs B, Comet D, Grange JC, Thibault P,. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. Br J Urol 1997; 80: 722-30
17. Aaronson NK, Ahmedzai S, Bergman B, et al,. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76
18. Scher HI, Steineck G, Kelly WK,. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 142-8
19. Murphy GP, Slack NH,. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1980; 1: 375-82
20. Eisenberger MA, Blumenstein BA, Crawford ED, et al,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
21. Fayers PM, Aaronson NK, Bjordal K, et al,. EORTC QLQ-C30 Scoring Manual, 3 edn. Brussels: European Organization for Research and Treatment of Cancer, 2001
22. Conti PD, Atallah AN, Arruda H, et al,. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; (4): CD005009
23. Loblaw DA, Virgo KS, Nam R, et al,. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596-605
24. Irani J, Celhay O, Hubert J, et al,. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008; 54: 382-91
25. Schasfoort E, Heathcote P, Lock T, et al,. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003; 169 (Suppl. 4): 387; abstract 1483
26. Hussain M, Goldman B, Tangen C, et al,. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450-6
27. Gleave M, Klotz L, Taneja SS,. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009; 27: 81-6
28. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 1491-8
29. Seruga B, Tannock IF,. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5: 574-6
30. Kumar RJ, Barqawi A, Crawford ED,. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005; 7 (Suppl. 5): S37-43
31. Higano C, Shields A, Wood N, Brown J, Tangen C,. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 1182-6
32. Yu EY, Gulati R, Telesca D, et al,. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 2668-73